Related Experiment Video

Updated: Feb 26, 2026

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.2K

INFLUENCE OF BETA-BLOCKERS AND IVABRADINE ON LONG-TERM PROGNOSIS OF PATIENTS WITH STABLE ANGINA

T Ilashchuk1, O Glubochenko1, B Senyuk1

  • 1Higher State Educational Establishment of Ukraine "Bukovinian State Medical University", Chernоvtsу, Ukraine.

Georgian Medical News
|July 21, 2017
PubMed

Insights

Ivabradine, when added to standard treatment for stable angina, reduced myocardial infarction and revascularization rates compared to beta-blockers. Patient adherence and specific biomarkers significantly impact long-term prognosis.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Stable angina management requires optimizing long-term patient prognosis.
  • Beta-blockers are a cornerstone therapy, but alternative or add-on treatments are continuously explored.

Purpose of the Study:

  • To compare the long-term prognostic influence of bisoprolol, carvedilol, and ivabradine in patients with stable angina.
  • To identify key factors affecting disease progression and patient outcomes.

Main Methods:

  • A 12-month observational study involving 90 stable angina patients receiving standard therapy plus bisoprolol, carvedilol, or ivabradine.
  • Analysis of treatment adherence, hospitalizations for myocardial infarction or circulatory decompensation, and prognostic endpoints using odds ratios.
  • Assessment of endothelial dysfunction markers like endothelin-1 and homocysteine.

Main Results:

  • Cardiovascular death and unstable angina occurred with similar frequency across all groups.
  • Patients receiving ivabradine showed fewer cases of myocardial infarction and a lower need for revascularization compared to beta-blocker groups.
  • Treatment adherence, age, heart rate, smoking, endothelin-1, and homocysteine levels were significant prognostic factors.

Conclusions:

  • Ivabradine may offer a prognostic advantage in stable angina by reducing myocardial infarction and revascularization events.
  • Long-term prognosis is strongly linked to patient adherence, physiological parameters, lifestyle, and endothelial dysfunction markers.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.9K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K